Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways by Piotrowski, Roman et al.
Address for correspondence: Dr Roman Piotrowski, Department of Cardiology, Grochowski Hospital, Postgraduate Medical 
School, ul. Grenadierów 51/59, 04–073 Warszawa, Poland, e-mail: rpiotrow@op.pl
Received: 17.06.2013 Accepted: 31.07.2013
299www.cardiologyjournal.org
ORIGINAL ARTICLE
Cardiology Journal 
2014, Vol. 21, No. 3, pp. 299–303
DOI: 10.5603/CJ.a2013.0121
Copyright © 2014 Via Medica
ISSN 1897–5593
Antazoline for rapid termination of atrial  
fibrillation during ablation of accessory pathways
Roman Piotrowski1, Tomasz Kryński1, Jakub Baran1,  
Piotr Futyma2, Sebastian Stec1, Piotr Kułakowski1
1Department of Cardiology, Grochowski Hospital, Postgraduate Medical School, Warsaw, Poland 
2Invasive Cardiology Department, St. Joseph’s Centre, Rzeszow, Poland
Abstract
Background and aim: To assess safety and efficacy of antazoline for termination of atrial 
fibrillation (AF) occurring during ablation of accessory pathways (AP).
Methods: We analyzed electrophysiological mechanism of antazoline (changes in A-A in-
terval) and the percentage of pre-excited QRS complexes before and after antazoline admini-
stration. The total dose administered and the time from the start of injection to sinus rhythm 
restoration were also measured.
Results: Out of consecutive 290 patients with Wolff-Parkinson-White syndrome undergoing 
radiofrequency (RF) ablation, 12 (4.1%) (4 females, mean age 36 ± 20 years) developed su-
stained AF which did not stop spontaneously within 10 min, and antazoline in 100 mg repe-
ated boluses was administered. In all 12 patients the drug restored sinus rhythm after a mean 
of 425 ± 365 s (range 43–1245 s) using a mean cumulative dose of 176 ± 114 mg (range 
25–400 mg). The drug slightly prolonged R-R intervals during AF (from 383 ± 106 to 410 ±  
± 70 ms) and reduced the percentage of fully pre-excited QRS complexes (from 35% to 26%). 
Intracardiac recordings showed gradual increase in A-A intervals, as well as regularization 
and decreasing fractionation of atrial activity following drug injection (mean A-A interval of 
162 ± 30 ms at baseline vs. 226 ± 26 ms shortly before sinus rhythm restoration, p < 0.001). 
AP was not completely blocked in any patient which enabled continuation of ablation.
Conclusions: Antazoline safely and rapidly converts AF into sinus rhythm during ablation of 
AP. The drug does not block AP completely, enabling continuation of ablation. The drug con-
verting AF into more organized atrial activity (atrial flutter/tachycardia) before sinus rhythm 
resumption. (Cardiol J 2014; 21, 3: 299–303)
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Introduction
Catheter ablation is an effective and curative 
treatment in patients with Wolff-Parkinson-White 
(WPW) syndrome. Atrial fibrillation (AF) may occur 
during the procedure and make ablation more dif-
ficult or impossible to perform due to intermittent 
pre-excitation, electrode instability or inability to 
map atrial insertion of the accessory pathway (AP). 
Usually AF stops spontaneously within seconds 
or minutes, however, in some patients it does not 
self-terminate. In such cases rapid conversion to 
sinus rhythm (SR) may be achieved by electrical 
cardioversion, however, it requires general anes-
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thesia and does not prevent from immediate AF 
recurrence. Antiarrhythmic drugs may terminate 
AF, however, they can also temporarily block AP 
and preclude ablation [1]. Therefore, a rapidly ac-
ting drug that terminates AF and does not totally 
block AP would be very useful.
Antazoline is an antihistaminic agent with 
antiarrhythmic quinidine-like properties [2–4]. 
In some countries it is registered for intravenous 
termination of cardiac arrhythmias and has been 
successfully used for many years for rapid termina-
tion of AF [5–8]. However, due to the lack of large 
randomized trials the drug is not listed in any for-
mal guidelines. The aim of our study was to assess 
safety and efficacy of antazoline for termination of 
AF occurring during ablation of AP.
Methods
Out of consecutive 290 patients with WPW 
syndrome undergoing radiofrequency ablation in 
2 institutions, 12 (4.1%) (4 females, mean age 36 ± 
± 20 years) developed AF which did not stop sponta-
neously or after Valsalva maneuver during 10 min 
and an operator decided that antazoline should 
be administered in order to restore SR. From the 
database, we collected demographic and clinical 
data, as well as electrophysiological parameters. 
The off-line analysis of intracardiac electrocar-
diograms (ECG) were performed to analyze atrial 
activity, ventricular response during AF, and the 
percentage of pre-excited QRS complexes before 
and after antazoline administration. The total dose 
administered and the time from the start of inje-
ction to sinus rhythm restoration was examined.
Antazoline was given intravenously in boluses 
of 100 mg injected over 2–3 min periods with 1 min 
interval between boluses. The maximal cumulative 
dose that could have been administered was 400 mg. 
A 12-lead ECG and intracardiac recordings, 
as well as blood pressure were continuously mo-
nitored. The drug was stopped immediately after 
SR restoration or when the maximal allowed 
cumulative dose was given. Antazoline was con-
traindicated when a patient had severe underlying 
cardiac disorder defined as heart failure symptoms 
in NYHA class > II or markedly reduced left ven-
tricular ejection fraction < 40%. Also significant 
hypotension (systolic blood pressure < 90 mm Hg) 
was a contraindication since the drug may cause 
hypotension.
Electrocardiographic measurements were ob-
tained at baseline and after antazoline administra-
tion, following each 100 mg bolus and just before 
termination of AF. Measurements were performed 
using electronic calipers from the tracings recor-
ded in the electrophysiological system at a speed 
of 100 mm/s. During AF, the shortest pre-excited 
R-R interval was measured in the lead with the 
most prominent pre-excitation. The percentage 
of pre-excited QRS complexes was calculated 
from a 30 s continuous ECG tracing by dividing 
the number of pre-excited beats and total number 
of beats during this period. Intracardiac atrial 
activity was analyzed from a diagnostic catheter 
introduced into coronary sinus. We measured 
duration of A-A intervals (consecutive atrial 
cycles during 30 s) and variability of A-A inter-
vals (standard deviation [SD] of consecutive A-A 
intervals during 30 s).
All patients gave informed written consent to 
undergo catheter ablation and to use their demo-
graphic, clinical and electrocardiographic data in 
further research. Catheter ablation was performed 
using standard methods. The patients were follo-
wed in the outpatient clinic to assess the long-term 
effect of the procedure.
Statistical analysis
The results are presented as mean ± SD or 
numbers and percentages. Numerical variables 
were compared using 2-sided paired t-test and 
qualitative variables — using c2 test with Yates 
correction or Fisher’s exact test where appropriate. 
A p value < 0.05 was considered significant.
Results
Demographic and clinical characteristics of 
the studied patients are presented in Table 1. 
Antazoline converted AF into SR in all patients. 
The drug was well tolerated and no side effects 
were noted. The mean effective cumulative dose 
Table 1. Demographic and clinical characteristics 
of studied patients.
Age [years] 36 ± 20
Male gender 8 (67%)
History of palpitations 11 (92%)
History of documented atrial fibrillation 3 (25%)
Overt pre-excitation 9 (75%)
Concomitant disorders
Arterial hypertension 1 (8%)
Coronary arterial disease 1 (8%)
Heart failure 0 (0%)
Diabetes mellitus 1 (8%)
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of antazoline was 176 ± 114 mg (range 25–400 mg) 
and the mean time to conversion — 425 ± 365 s 
(range 43–1245 s).
The effects of antazoline on electrocardio-
graphic and electrophysiological parameters are 
presented in Table 2 and Figures 1 and 2. The drug 
slightly prolonged R-R intervals during AF and ten-
ded to reduce the percentage of pre-excited QRS 
complexes. Intracardiac recordings showed gradual 
significant increase in A-A intervals and regulari-
zation of atrial activity following drug injection.
Although the drug reduced the degree of pre-
-excitation, AP was not completely blocked in any 
patient which enabled continuation of ablation, 
both in patients with overt WPW and in those with 
concealed AP. No further AF recurrences during 
ablation were noted. All procedures were effective 
and there were no recurrences of pre-excitation or 
palpitations during follow-up period (mean 29 ± 26 
months, range 4–93 months).
Discussion
The main findings of the present study are 
that antazoline effectively and rapidly converts AF 
into SR during ablation of AP. Although the drug 
prolongs refractory period of AP, it does not block 
AP completely, enabling continuation of ablation. 
The study also shows that antazoline is safe in 
termination of AF in WPW patients.
When AF develops during ablation of AP, it may 
complicate continuation of the procedure. The cat-
heter is less stable and the pre-excitation during AF 
may be variable with some beats completely without 
pre-excitation. Although in some patients with overt 
pre-excitation the procedure may be continued du-
ring AF and effective AP conduction abolition may be 
achieved, applications delivered during SR are more 
accurate and probably more effective. Moreover, in 
patients with concealed AP, AF precludes effective 
procedure because the atrial insertion of AP cannot 
be identified. Thus, prompt and durable restoration 
of SR is desired in the majority of patients.
Antazoline has been used for rapid AF termi-
nation in some countries for many years, however, 
due to the lack of large, randomized studies it is not 
mentioned in the guidelines as the agent recom-
mended for AF termination. There is an ongoing 
trial which will establish the role of antazoline in 
this setting [9]. The drug has quinidine-like an-
tiarrhythmic properties, including prolongation of 
conduction and refractoriness. It has a relatively 
short half-life time of 3 h and electrophysiological 
effects disappear after 1 h [3] which is especially 
important when only short-lasting and transient 
changes in electrophysiological parameters are 
Table 2. Effects of antazoline on electrocardiological and electrophysiological parameters during atrial 
fibrillation.
Parameter Before antazoline After antazoline* P
Shortest R-R interval [ms] 383 ± 106 410 ± 70 NS
Percent of pre-excited QRS complexes 35 26 NS
Mean A-A interval [ms] 162 ± 30 227 ± 26 0.001
Variability of A-A intervals [ms] 30 26 NS
*Total cumulative dose
Figure 1. Changes in analyzed parameters following 
consecutive doses of antazoline; A. Mean A-A intervals; 
B. Percent of pre-excited QRS complexes.
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Figure 2. Intracardiac recordings at baseline (A), at the onset of atrial fibrillation (B), after antazoline administration 
shortly before atrial fibrillation termination (C) and after restoration of sinus rhythm (D). In panels B and C gradual 
lengthening of A-A intervals is seen; CS — diagnostic catheter placed in coronary sinus; MAP — ablation catheter, 
I, II, III, aVF, V1, V6 — surface ECG.
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required. The drug acts rapidly, terminating AF 
within 10–20 min from the start of injection [7]. 
Observational studies showed that overall efficacy 
of the drug in short-lasting AF ranges between 
6% and 81% [2, 7], exceeding 50% in the largest 
reported cohort of 1325 patients [8]. One study 
showed that antazoline was completely ineffective 
in termination of permanent AF [10].
The above-mentioned antazoline properties 
prompted its usage during electrophysiological 
procedures in some laboratories. We also have been 
successfully using antazoline for a long-time not 
only in the electrophysiology laboratory but also 
in the emergency department or cardiac intensive 
care unit. The drug is contradicted in patients with 
severe heart failure or markedly reduced left ven-
tricular ejection fraction due to modest negative 
inotropic effect and also because there is usually 
transient increase in ventricular response during 
AF following drug administration which may be 
dangerous in patients with severe cardiac disease. 
The latter effect is probably due to the gradual 
reduction of the number of fibrillatory waves in 
the atrium, resulting in less concealed conduction 
in the atrio-ventricular node which promotes 
conduction from the atria to the ventricles and 
fastens ventricular rate. This phenomenon is simi-
lar to that seen following administration of other 
antiarrhythmic agents such as quinidine, ajmaline 
and flecainide or propafenone.
Our results showed that antazoline not only 
terminated AF but also prolonged probably refrac-
toriness of the AP, seen as the reduction of the 
percentage of the pre-excited QRS complex during 
AF. While such an effect is desirable during any 
chronic antiarrhythmic therapy in a patient with 
WPW syndrome, it is unwanted during ablation 
because drug-induced block in the AP usually 
precludes proper mapping and ablation of AP. 
However, in all our patients antazoline did not 
completely block the AP and all procedures were 
successfully completed. Thus, we believe that 
antazoline can be used in this situation instead of 
electrical cardioversion which requires anesthe-
sia and does not prevent from AF recurrence, or 
other antiarrhythmic drugs such as flecainide or 
propafenone which may block AP completely and 
have slower onset of action and longer duration of 
electrophysiological effects on AP.
Another advantage of using antazoline is 
its very low price (currently 1 euro per 200 mg 
dose) which is much less than the cost of another 
antiarrhythmic drug such as propafenone or ver-
nakalant, used in this setting.
Limitations of the study
This was a retrospective analysis of our da-
tabase and the number of patients was small. The 
study was not randomized and not controlled by 
placebo. We did not perform systematically pro-
grammed atrial and ventricular stimulation follo-
wing antazoline administration and AF termination, 
thus, detailed effects of the drug on the conduction 
and refractoriness of the atrio-ventricular node 
and AP were not examined. We did not measure 
drug plasma levels, thus, correlation between drug 
concentration, effectiveness in AF termination, and 
effects on electrophysiological properties of AP 
and atrio-ventricular node could not be examined.
Conclusions
Antazoline safely and rapidly converts AF into 
SR during ablation of AP. The drug does not block 
AP completely, enabling continuation of ablation. 
The drug gradually increases A-A intervals during 
AF converting it into more organized atrial activity 
(atrial flutter/tachycardia) before SR resumption. 
The on-going multicenter randomized studies 
will establish the role of antazoline in acute AF 
termination.
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